Journal of Clinical Oncology
Articles in this Issue
Neoadjuvant carboplatin/taxane (CbT) with or without doxorubicin/cyclophosphamide (AC) in real-world patients with early triple negative breast cancer (TNBC).
e23347 Background: Treatment (tmt) of early-stage TNBC has changed over the past several years with Cb becoming a standard addition to AC-T. Whether AC sh...
Optimizing evidence-based, patient-centered care in bladder cancer in community-based settings: A Project ECHO initiative.
e16607 Background: There has been a significant shift in the treatment landscape for bladder cancer (BC) with the incorporation of immunotherapy (IO) into...
Unraveling gut gram-negative antibiotic-resistant colonization dynamics in hematologic cancers: Insights from bioinformatics and immune signatures.
10031 Background: Infections account for ~60% of cancer-related deaths. Hematologic cancers have a 3x higher infection-related mortality than solid tumors...
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer—The IKF/AIO-ADJUBIL trial.
4132 Background: Patients (pts) with biliary tract cancer (BTC) still have a poor outcome with limited effective treatment options (only 20% of pts eligib...
Evaluation of sleep quality and quality of life among patients newly diagnosed with head and neck cancer.
11131 Background: Patients diagnosed with head and neck cancer (HNC) often suffer from distress attributed to their cancer diagnosis which may disturb the...
Age-related macular degeneration in individuals with clonal hematopoiesis.
6517 Background: Clonal hematopoiesis (CH), an age-related condition involving somatic mutations in blood stem cells, increases the risk of myelodysplasti...
Keeping an eye on immune effector cell-associated neurotoxicity syndrome (ICANS): Outcomes and predictors of mortality.
e23090 Background: CAR-T cell therapy has become a valuable tool in treatment of certain hematologic malignancies. Immune Effector Cell-Associated Neuroto...
Boolean network modeling: The first step toward a new understanding of breast cancer heterogeneity.
e15100 Background: Intratumoral heterogeneity, driven by phenotypic plasticity, contributes to disease progression and therapy failures. However, a thorou...
A multi-omic liquid biopsy for the earlier detection of pancreatic cancer.
e16453 Background: Early diagnosis is the central challenge in pancreatic ductal adenocarcinoma (PDAC) and the successful development of an early detectio...
Comprehensive metabolite profiling of FFPE tissue to analyze metabolic changes in colorectal cancer.
e15716 Background: Although fresh-frozen samples are currently the gold standard when performing mass spectrometry-based metabolomics, clinical workflows...
Procedure considerations for image-guided intratumoral immunotherapy: A retrospective study of 357 cases.
e14644 Background: Tumor in situ immunotherapy functions as an "in situ vaccine," eliciting a systemic immune response. However, detailed reports on the o...
Preliminary results of anlotinib combined with gemcitabine and docetaxel for recurrent or metastatic primary malignant bone tumors: An open-label, single-arm, multicenter clinical trial.
e23507 Background: Recurrent or metastatic primary malignant bone tumors were associated with poor prognosis and limited treatment options. Anlotinib, a m...
Employing novel pan-cancer targets for immunotherapy in leukemias and solid tumors.
2582 Background: Acute myeloid leukemia (AML) and many solid tumors are difficult to treat. Tumor-associated protein targets that are the focus of cancer...
ARIMA prediction model for mortality caused by metastatic cancers in the United States population up to the year 2050: A CDC WONDER Database analysis.
11157 Background: Metastatic cancers are the leading cause of mortality in the United States (US). In this study of death certificates, obtained from data...
Comparison of the efficacy and safety of regorafenib monotherapy and regorafenib combination therapy in the third-line treatment of metastatic colorectal cancer: A real-world study.
e15529 Background: Regorafenib is a novel tyrosine kinase inhibitor (TKIs) approved in third-line of treatment for patients with metastatic colorectal can...
Busulfan and cyclophosphamide vs busulfan and fludarabine for myeloablation in the patients of acute myeloid leukaemia/ myelodysplastic syndrome undergoing stem cell transplant: A systematic review and meta-analysis.
e18545 Background: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are key indications for hematopoietic stem cell transplantation (HSCT)....
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data.
9554 Background: An ITC comparing NIVO + RELA and NIVO + IPI, approved dual immunotherapy treatment options for patients (pts) with advanced melanoma, was...
A single institution review of early onset colorectal cancer: 10 year retrospective clinical study.
e15675 Background: The incidence of early onset (EO) colorectal cancer is on the rise in the western world, with approximately 10% of all new cases diagno...
Assessing the contribution of metabolic risk factors to uterine cancer-related deaths and predictions until 2030 and 2050.
e17642 Background: The incidence of uterine cancer has been rising globally, particularly in Western countries. This could be due to an unhealthy lifestyl...
Genomic profiling of colorectal liver metastasis and insight into their prognostic value.
e15536 Background: Colorectal liver metastases (CRLM) pose a significant clinical challenge, characterized by high recurrence rate even after surgical res...
Single-cell analysis explores GJB2-mediated interactions in cancer-associated pericyte subgroups that promote lymph node metastasis in lung adenocarcinoma.
e20012 Background: Lymph node metastasis remains a critical determinant of recurrence and adverse outcomes in invasive lung adenocarcinoma (IAC)....
Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial).
1009 Background: Patients with Stage II/III breast cancer that overexpresses the human epidermal growth factor-2 (HER2+) or is triple-negative (TNBC) gene...
An early colorectal cancer screening programme based on bisulfite-free sequencing of methylated circulating tumor DNA.
3617 Background: Colorectal cancer (CRC) screening tests based on colonoscopy and fecal DNA testing are limited due to their invasive nature and low compl...
HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay.
3074 Background: Homologous recombination and repair (HRR) deficiency (HRD) is characterized by genomic instability associated with mutations in BRCA1/2 o...
A meta-analysis of safety and efficacy of datopotamab deruxtecan and sacituzumab govitecan for second line treatment of metastatic non-small cell lung cancer (NSCLC).
8575 Background: Subsequent line treatment options for metastatic NSCLC remain limited. We sought to analyze the efficacy and safety of two Anti-TROP-2/to...